Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (603456.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 15.43

From 52W high−28.17%

Volume26.03M

Market capCNY 13.85B

P/E (TTM)19.0x

P/S (TTM)2.6x

Div yield1.29%

Key dataSep 18, 2026

Open

CNY 15.43

From 52W high

−28.17%

Volume

26.03M

Market cap

CNY 13.85B

ValuationView details →

P/E (Fwd)

15.8x

EV/EBITDA

9.2x

P/E (TTM)

19.0x

RSI (14)

51.5

MomentumView details →

1D Return

−5.36%

YTD Return

−13.30%

ValuationView details →

P/E (Fwd)

15.8x

P/E (TTM)

19.0x

EV/EBITDA

9.2x

EV/Sales

2.4x

P/S (TTM)

2.6x

P/B (TTM)

1.6x

ProfitabilityView details →

Gross Margin

36.58%

Net Margin

12.49%

EBITDA Margin

25.73%

ROE (TTM)

7.33%

ROA (TTM)

6.16%

Asset Turnover

0.49x

GrowthView details →

Revenue YoY

+0.85%

EPS YoY

+5.46%

FCF YoY

+78.99%

Revenue CAGR 3Y

+0.39%

EPS CAGR 3Y

−9.60%

EBITDA YoY

—

MomentumView details →

1D Return

−5.36%

YTD Return

−13.30%

1Y Return

−19.83%

RSI (14)

51.5

vs 50D SMA

−0.07%

vs 200D SMA

−3.33%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

3.83x

Quick Ratio

2.79x

Div Yield

1.29%

Div Rate

CNY 0.20

Div Growth 1Y

−60.00%

EarningsView details →

EPS (Actual)

CNY 0.24

EPS Surprise

−17.25%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.28

Avg Surprise (4Q)

−17.25%

Rev Surprise

−0.67%

Financials snapshotView financials →

Revenue (TTM)

5.22B

Net Income (TTM)

651.95M

Op. CF (TTM)

1.67B

Next earningsOct 23, 2026 →

Latest newsMore news →

Jiuzhou Pharmaceutical's wholly-owned subsidiary Jiuzhou Biomedicine (Taizhou) received drug registration certificates from China's National Medical Products Administration for its buspirone citrate tablets in 5mg and 10mg strengths.17d ago

Jiuzhou Pharmaceutical disclosed that its CDMO business new orders grew steadily in H1 2026, adding 66 early-stage clinical projects, 5 Phase III-to-pre-launch projects, and 5 commercial projects.35d ago

Similar companies

海正药业600267.SH 华润江中600750.SH Neurocrine Biosciences, Inc.NBIX Fujian Haixi Pharmaceuticals Co., Ltd.02637.HK 健友股份603707.SH 浙江医药600216.SH Find similar companies →

Latest newsMore news →

Jiuzhou Pharmaceutical's wholly-owned subsidiary Jiuzhou Biomedicine (Taizhou) received drug registration certificates from China's National Medical Products Administration for its buspirone citrate tablets in 5mg and 10mg strengths.17d ago Jiuzhou Pharmaceutical disclosed that its CDMO business new orders grew steadily in H1 2026, adding 66 early-stage clinical projects, 5 Phase III-to-pre-launch projects, and 5 commercial projects.35d ago